| Copanlisib studied in …STUDIED_INderived72 of 72show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 72 trials list this drug (15 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03842228Phase 1 · active not recruiting Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations · 72 trials list this drug (15 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03939897Phase 1 · active not recruiting Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · 72 trials list this drug (15 active) | — | — | Breast Neoplasm,Breast Carcinoma,HER2-Negative Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · 72 trials list this drug (15 active) | — | — | Chronic Lymphocytic Leukemia,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03502733Phase 1 · active not recruiting Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma · 72 trials list this drug (15 active) | — | — | Lymphoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04345913Phase 1/Phase 2 · active not recruiting Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · 72 trials list this drug (15 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04263584Phase 2 · completed Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL · 72 trials list this drug (15 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 72 trials list this drug (15 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Endometrial Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04317105Phase 1/Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN · 72 trials list this drug (15 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06360588Phase 2 · active not recruiting Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) · 72 trials list this drug (15 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06400238Phase 2 · active not recruiting Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) · 72 trials list this drug (15 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03474744Phase 2 · active not recruiting Copanlisib and Rituximab in Marginal Zone Lymphoma Patients · 72 trials list this drug (15 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05490771Phase 2 · active not recruiting Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) · 72 trials list this drug (15 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04939272Phase 1/Phase 2 · active not recruiting Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · 72 trials list this drug (15 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02705859Phase 1 · completed Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) · 72 trials list this drug (15 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03789240Phase 2 · active not recruiting Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03581942Phase 1/Phase 2 · completed Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) · 72 trials list this drug (15 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05082025Phase 2 · terminated Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations · 72 trials list this drug (15 active) | — | — | Malignant Ovarian Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04572763Phase 1/Phase 2 · active not recruiting Copanlisib Plus Venetoclax in R/R DLBCL · 72 trials list this drug (15 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895579Phase 1 · completed Lung Cancer With Copanlisib and Durvalumab · 72 trials list this drug (15 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02367040Phase 3 · completed Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108858Phase 1/Phase 2 · terminated Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer · 72 trials list this drug (15 active) | — | — | Breast Neoplasm,Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03711058Phase 1/Phase 2 · completed Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04462471Phase 1 · completed Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers · 72 trials list this drug (15 active) | — | — | Thyroid Gland Follicular Carcinoma,Malignant Thyroid Gland Neoplasm,Thyroid Gland Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04433182Phase 2 · terminated Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma · 72 trials list this drug (15 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042051Phase 1 · terminated Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · 72 trials list this drug (15 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05687721Phase 1/Phase 2 · withdrawn Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · 72 trials list this drug (15 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03432741Phase 1 · terminated Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer · 72 trials list this drug (15 active) | — | — | Breast Carcinoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04685915Phase 2 · withdrawn Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL · 72 trials list this drug (15 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253262Phase 1/Phase 2 · active not recruiting A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer · 72 trials list this drug (15 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04750941Phase 2 · terminated Study of Copanlisib and Ketogenic Diet · 72 trials list this drug (15 active) | — | — | Follicular Lymphoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03484819Phase 2 · completed Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma · 72 trials list this drug (15 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626455Phase 3 · terminated Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218667Phase 1/Phase 2 · withdrawn A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer · 72 trials list this drug (15 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05217914completed A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04431635Phase 1 · terminated Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma · 72 trials list this drug (15 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01660451Phase 2 · completed Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933617Phase 1 · terminated Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas · 72 trials list this drug (15 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05387616Phase 2 · unknown A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden · 72 trials list this drug (15 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 72 trials list this drug (15 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06238583no longer available Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors · 72 trials list this drug (15 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803123early Phase 1 · terminated Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL · 72 trials list this drug (15 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03458728Phase 1/Phase 2 · terminated Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients · 72 trials list this drug (15 active) | — | — | Lymphoma,Ewing Sarcoma,Osteosarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02369016Phase 3 · completed Phase III Copanlisib in Rituximab-refractory iNHL · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03735628Phase 1 · completed An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors · 72 trials list this drug (15 active) | — | — | Head and Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05295589Phase 2 · withdrawn Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy · 72 trials list this drug (15 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Resistant Primary Peritoneal Carcinoma,Primary Peritoneal Endometrioid Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03803761Phase 1/Phase 2 · withdrawn A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer · 72 trials list this drug (15 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156828Phase 1 · terminated Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02342665Phase 1/Phase 2 · completed Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03877055Phase 1/Phase 2 · completed A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma · 72 trials list this drug (15 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03128619Phase 1 · terminated Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer · 72 trials list this drug (15 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03517956Phase 1 · completed Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02535247Phase 1/Phase 2 · terminated Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma · 72 trials list this drug (15 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03052933Phase 1/Phase 2 · completed Copanlisib and Gemcitabine in Relapsed/Refractory PTCL · 72 trials list this drug (15 active) | — | — | Mature T-Cell and NK-Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010096Phase 1 · withdrawn BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors · 72 trials list this drug (15 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04155840Phase 2 · terminated Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 72 trials list this drug (15 active) | — | — | Lymphoid Leukemia,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03886649Phase 1 · terminated Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02728258Phase 2 · completed Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer · 72 trials list this drug (15 active) | — | — | Endometrioid Adenocarcinoma,Endometrial Endometrioid Adenocarcinoma,Endometrial Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02631590Phase 2 · completed Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma · 72 trials list this drug (15 active) | — | — | Digestive System Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498430Phase 1 · completed Copanlisib Chinese PK Study · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03172884Phase 1 · completed Study of Copanlisib in Hepatic or Renal Impairment · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02822482Phase 1/Phase 2 · terminated Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss · 72 trials list this drug (15 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02253420Phase 1 · completed COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04233697Phase 1 · withdrawn Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma · 72 trials list this drug (15 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02391116Phase 2 · completed Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · 72 trials list this drug (15 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03377101Phase 2 · withdrawn Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer · 72 trials list this drug (15 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01404390Phase 1 · completed Japanese BAY80-6946 Monotherapy Phase I Study · 72 trials list this drug (15 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01411410Phase 1 · completed Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer · 72 trials list this drug (15 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00962611Phase 1 · completed BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer · 72 trials list this drug (15 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01460537Phase 1 · completed Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer · 72 trials list this drug (15 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02455297Phase 2 · terminated Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) · 72 trials list this drug (15 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02155582Phase 1 · completed Copanlisib Pharmacodynamic Study · 72 trials list this drug (15 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |